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THE NATIONAL NETWORK OF DEPRESSION CENTERS:
PROGRESS THROUGH PARTNERSHIP
John F. Greden, M.D., is the Executive Director of the University of Michigan Comprehensive
Depression Center and Founder and Chair of the National Network of Depression Centers
(NNDC). His academic activities include 28 years of NIH-funded projects studying major
depressions and bipolar disorders, emphasizing biomarker and clinical correlates of depression
and bipolar disorders over a patient’s lifetime. These include hypothalamic–pituitary–adrenal
(HPA), neuroimmune, sleep laboratory, and psychomotor measures; causes and interventions for
Treatment Resistant Depression (TRD); and prevention of depressive recurrences. He served 22
years as Chair of the University of Michigan Department of Psychiatry, is the author or co-
author of 265 peer-reviewed publications or books, has given approximately 410 invited
presentations, supervised 14 NIH ‘‘K’’ and Veterans Administration Career Development young
investigator awardees, and continually seeks to promote translational themes to educate a new
generation of clinical investigators. He served as Past President of the Society of Biological Psychiatry and the
Psychiatric Research Society and as a Co-Editor of the Journal of Psychiatric Research for 7 years. In 2001, he
founded and still directs the University of Michigan Comprehensive Depression Center, patterned after the nation’s
Cancer Centers. In 2007, he led formation of the NNDC, which currently includes 22 of the nation’s leading
academic medical centers and is the focus of this article.
THE CHALLENGE
The time has come to meaningfully transform our
nation’s strategies for counteracting the scourges of
depressive and bipolar illnesses.
Hundreds of excellent studies confirm that major
depressive disorders, bipolar illnesses, and related
disorders afflict an estimated one of every five
Americans, lead the United States and the world in
disease burden and disability, and account for more
than 30,000 U.S. citizens’ deaths annually by suicide
while thousands more die earlier because of associated
medical consequences. Mood disorders are second in
contributing to America’s health costs, trailing only
cardiovascular diseases.[1–6] Hundreds of additional
studies provide substantial understanding of why these
disorders produce such huge burdens (Table 1). It is
reasonable to conclude we have thoroughly identified
the challenges associated with the prevalence, burdens,
disabilities and costs of depressions, and bipolar




The time has come to fight depression and bipolar
illnesses by adapting network and data sharing strategies
previously shown to be successful for other chronic
disorders and to implement a vision that enables every
resident in the United States to be within 200 miles of the
expertise needed to better diagnose, treat, and pre-
vent clinical depression and bipolar illnesses. The founda-
tion for such an effort is underway via the recently
established National Network of Depression Centers
(NNDC), patterned after the nation’s networks of cancer
centers. This article will describe the National Network
of Depression Centers www.NNDC.org, its origins,
progress to date, and the academic, federal, community,
and corporate partnerships that are either developed or
still required.
WHY THE NEED FOR A NETWORK?
Despite years of growth in research dollars for
neuroscience and mental health, breakthroughs for
those brain disorders producing depression, bipolar
illnesses, and related conditions have been sparse and
global progress may be stalled even more because of
growing economic constraints.[7] Other contributing
reasons are obvious and arguably would be improved
using the power of networks and partnerships.[8–10]
First, mental health investigators and clinicians have
not adopted a common language for characterizing and
monitoring clinical severity and outcomes, have not
adopted standardized ‘‘vital signs’’ for mood disorders
comparable to blood pressure readings for hyperten-
sion, and have not routinely employed measurement-
based care despite evidence that it improves outcomes.
Network adoption of a ‘‘common language’’ will
accelerate the improvements being sought.
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Second, mental health literature is replete with clinical
trials characterized by small numbers, ranging from 40 to
70. In comparison, cancer, cardiovascular, and diabetes
chronic care specialists, utilizing established, financially
supported, large and ongoing network collaborations,
long ago moved to multi-site, standardized, longitudinal
studies of thousands or tens of thousands to address
vitally important clinical questions that characterize
chronic disorders, such as whether antidepressant
medications reduce or accentuate suicide risk.[5] When
studying complex genetic diseases with multiple etiolo-
gies or searching for biomarkers, small samples are
antithetical to adequate statistical power. Networks are
necessary to substantially counteract that shortfall.
Third, the focus of these research studies needs to be
shifted to a lifetime perspective. Depression and bipolar
disorders are long-term and chronic in their course
while our study strategies are short-term and acute.
While arrays of successful ‘‘mini-networks’’ have been
established, almost always supported by grant projects
with a sundown clause, the real need is sustainability to
assess longitudinal course and maintenance of stability,
comparable to diabetes mellitus. During the past decade,
NIH-funded clinical trials that became well-known by
their acronyms such as STARD, TADS, TORDIA,
STEP-BD, and others[11,12] have been successful in
generating useful information but frustrating in not
producing translational breakthroughs that attain and
maintain wellness.[13,14] Filling these voids is essential.
Mini-network launches require considerable money,
months, or years and just when each has matured
enough to enroll and retain a cadre of research
participants and investigators, it tends to be disbanded.
Articles appear; clinical breakthroughs remain elusive.
These problems are neither new nor unique to brain
research and mental health,[8] but other fields have
moved more rapidly to adopt network solutions. The
void in mental health fields at least partially explains
why Unutzer[14] concluded in 2009 that over the past
decade ‘‘epidemiological research on the prevalence of
depressive and anxiety disorders does not show any





Other chronic disease specialties have addressed
translational network shortcomings by establishing and
relying upon academic-private-community-federal colla-
borations. For these to function effectively, a federal
component is generally required. The National Cancer
Institute (NCI) Network serves as perhaps the best-
known prototype. This network is credited with improv-
ing outcomes for those with cancer, in some cases
dramatically.[15] In 1954, childhood leukemia victims
survived an average of only months. Now, aided by
translational advances developed by and disseminated
through NCI-supported comprehensive cancer center
faculty and staff members, more than 80% are cured. The
Director of the National Cancer Institute (NCI) in 2006
stated that ‘‘The cancer centers have been and continue to
be the crown jewels of the NCI’s program.’’[16] Large
samples are their norm. Cancer stigma concomitantly has
been remarkably reduced. Whispered references to ‘‘The
Big ‘C’’’ were once the cultural perspective. No longer.
The United States now has more than 70 Cancer Centers
across the country proudly displaying their names,
accomplishments, and philanthropic gains. Cardiovascular
Centers of Excellence similarly have aided an approximate
50% reduction of death rates from heart disease over the
past 40 years. Partially motivated by all these reasons,
leaders in counteracting other chronic illnesses, such as
autism, Parkinson’s disease, and Alzheimer’s disease, have
learned the power of sustainable networks.
Over the same span of decades, depressive and
bipolar illnesses—statistically more burdensome and
expensive than cancers[17] remained relatively hidden,
secreted away, and out of the mainstream while suicide
rates, most associated with depression and bipolar
illnesses, experienced no significant decrease.[5]
It should not be overlooked that funding growth for
cancer has greatly exceeded that for mental health
research despite depression’s burden by itself exceeding
those for cancers; collective voices are more often
heard. A new model is needed—a network model
already proven to work and to focus greater attention
and resources on these most-burdensome of diseases.
WHAT IS A COMPREHENSIVE
DEPRESSION CENTER?
The formation of the NNDC is predicated upon the
existence of individual centers of excellence for depres-
TABLE 1. Contributors to huge global burden of
disease for major depressive disorders and bipolar
illnesses
1. High prevalence and peak symptom onset during ages 15–24
2. Persistent stigma
3. Under-diagnosis, under-treatment, inappropriate treatment, or
no treatment for millions
4. Complex gene-environment underpinnings that have thus far
eluded translation into treatments
5. Unavoidable stressors precipitating or exacerbating episodes
6. Current ‘‘first-line’’ treatments that do not routinely achieve
clinical remission; an episodic, recurrent, usually lifetime pattern
that worsens and becomes more treatment resistant and chronic;
possible cumulative alterations in brain gene expression,
neurotrophins, circuitry, and morphology
7. Development of Treatment-Resistant Depression (TRD) for
approximately one-third of the millions with mood disorders
8. Relatively infrequent use of effective, long-term maintenance
treatments despite their value in preventing prevent recurrences
9. Few large-sample studies of biomarkers and outcomes, leading to
absence of personalized treatments; and;
10. Apparent de-emphasis of industry efforts to produce more
effective, safer antidepressant or mood-stabilizing medications
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sion, bipolar illness, and related conditions that are
coupled with commitments to advance and disseminate
knowledge. In 2001, the Board of Regents of the
University of Michigan approved a proposal to establish
presumably the first large-scale Comprehensive Depres-
sion Center, patterned after the nation’s Cancer
Centers. The original fivefold Mission remains: (1) Find
depressive and bipolar illnesses earlier in life by
implementing cost-effective widespread prevention-
oriented screening; during ages of peak onsets;[18]
(2) Treat earlier when most treatable and attain the
ever-important recovery;[19] (3) Prevent recurrences and
maintain wellness; while primary prevention remains a
vision, secondary prevention of depressive episodes is
effective but inadequately prescribed;[20–22] (4) Coun-
teract stigma, an essential mission if other aims are to be
achieved;[23] and (5) Transform public policy,[24] starting
with catalyzing a national network of depression centers
patterned after the nation’s network of cancer centers.
This fifth goal is the primary focus of this article.
A comprehensive center denotes a virtual home base
dedicated to the integration and subsequent dissemina-
tion of research, clinical care, education, and public
policy. Comprehensive networking implies interdisci-
plinary collaboration, standardization, data sharing,
lifetime perspectives, and a dedication to tackling and
translating truly important, unanswered clinical chal-
lenges. It supports infrastructure venues that enable
basic science investigators and their clinical colleagues
to readily partner, plan, test, continually improve,
export and sustain translational strategies. and export
translational strategies. ‘‘Comprehensive’’ creates an
expectation that the search for new knowledge is
incomplete until disseminated and implemented in
primary care and community settings where most
mental health problems are treated; and that preven-
tion programs deserve an equal seat at the research and
clinical tables. Perhaps, most pivotal and admittedly
difficult to achieve with traditional well-established
departmental structures that segment by age, ‘‘com-
prehensive’’ mandates efforts to understand and inte-
grate efforts across the lifespan, extending from
perinatal through elderly, again similar to lifetime
clinical efforts to manage diabetes mellitus. Public
health and self-management principles are valued,
emphasized, taught, measured, and steadily improved.
For obvious practical reasons, Comprehensive Depres-
sion Centers, similar to Cancer Centers, rely upon a
firm, sustainable infrastructure that does not require
expensive rebuilding after completion of each project.
Education of providers, the public, third-party payers,
and a new generation of interdisciplinary scholars is
recognized as essential. And collaboration with public
policy leaders is perceived as essential and laudable.
‘‘Comprehensive’’ further denotes the antithesis of
‘‘silo,’’ a colloquial and pejorative term for working in
isolation. A ‘‘network of centers’’ does not, however,
denote an expectation that every struggling patient or
family member should travel to some distant ‘‘Ivory
Tower.’’ Rather, the expectation is that knowledge,
treatments, and preventive practices emanating from these
Centers will be more rapidly disseminated and
imbedded into the front-lines of health care.
Adapting NIH-NCI principles, in 2001 the University
of Michigan Depression Center was strategically proposed
to be interdisciplinary and broadly based. It was designed
to serve as a focal point for collaboration for more than
150 depression and bipolar faculty members and trainees
from 33 departments and 13 of the University’s schools,
colleges and institutes, and promote integration in new
studies, community outreach, clinical delivery, evidence-
based education, stigma reduction, and public policy. The
Center is administratively housed in the Department of
Psychiatry. Initial financial support was blended from the
University, a National Institute of Health (NIH)-Na-
tional Center for Research Resources (NIH-NCRR)
grant of $4 million, the Department of Psychiatry,, and
approximately $15 million from donors (these indis-
pensible development dollars have since expanded
three-fold). Such combined support enabled construc-
tion of an innovative and attractive research and clinical
facility—the ‘‘antithesis of depression’’—that opened in
2006 and serves as the physical hub from which an
array of ‘‘virtual’’ studies and projects are coordinated.
The facility, also housing ambulatory psychiatry
programs, is a tremendous boon but not the indis-
pensible component. Rather, patients, families, faculty,
staff, community volunteers, friends, collaborators, and
supporters are the core of any Center. To help
overcome stigma, the University of Michigan ‘‘Depres-
sion Center’’ proudly acknowledges its name.
TRANSITION TO A NATIONAL
NETWORK
The Michigan Depression Center’s original mission
emphasized that one Depression Center is not enough to
address national data-sharing needs. It is recognized that
an integrated national network was required, tying
Centers of Excellence together with satellite clinics,
community partnerships, imbedding strategies, care
managers and outreach programs such as telehealth.
Only then will essential data be generated and translated
to advance diagnosis and treatment, refine health delivery
systems, deliver better care at manageable cost to the vast
number of untreated and underserved populations, and
meaningfully address preventive strategies.[25]
In 2007, following encouragement by members of the
University of Michigan Depression Center’s National
Advisory Board, invitations to participate in launching
the NNDC were extended. In 2008, an inaugural
meeting was held at the University of Michigan
Depression Center. Aided by indispensable support from
students and faculty at the Ross School of Business at the
University of Michigan throughout 2008, representatives
from 16 founding member institutions drafted and
adopted a charter (www.NNDC.org). Requirements
for participating Centers are summarized in Table 2.
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Twenty-one academic universities (Table 3 and Fig. 1)
currently belong to the NNDC. Annual growth is under-
way. Global federations or networks are being discussed.
INITIAL AIMS OF THE NNDC
Selected initial aims for the NNDC included (1)
investigating important, unanswered research transla-
tional questions through establishment of outreach
partnerships with primary care and specialties at high-
risk for mood disorders; (2) developing and routinely
using a common clinical language and standardized
outcome measures; (3) creating large research registries
and ‘‘truly large’’ standardized data bases; (4) screening
early and promoting a lifelong perspective for these
chronic diseases; (5) developing and testing biomarkers
and the new and improved treatments that we so sorely
need; (6) collaborating with advocacy groups and others
to counteract stigma; (7) developing and disseminating
real-time disease guidelines; and (8) emphasizing pro-
grams to maintain recovery and wellness. NNDC
members concluded early that the network must ‘‘partner,
share and leverage’’ its talents, expertise, organizational
stability, and resources with those of others, notably
striving to work with NIMH and other NIH Institutes,
SAMHSA, CTSAs, Agency for Health Research Quality
(AHRQ), VAH, DOD, Foundations, and potential
corporate partners. Network collaborations may help
overcome seemingly insurmountable obstacles by study-
ing drug, neuromodulation, psychotherapy and other
combinations from the inception of treatment to ‘‘attack
the disease on multiple fronts,’’ comparable to the
strategies used for HIV and currently being assessed for
cancer. As Paoletti was recently quoted as stating (26)
when describing pharmaceutical efforts to use drug
combinations at earlier stages, ‘‘You don’t kill cancer in
only one way.’’ The same may prevail for depression,
since fewer than 40% attain wellness using traditional
treatment approaches for the first episode (11).
These aims are extensive—intentionally so. Some
health networks or societies devote their efforts to one
or two ‘‘legs of a table,’’ such as research and advocacy.
NNDC inaugural members concurred that by lever-
aging their existing strengths, an integrated approach
could and should incorporate four legs—research,
clinical translation, education, and public policy.
SELECTED NNDC
ACCOMPLISHMENTS TO DATE
In the first year, four Domain Committees (Re-
search, Clinical, Educational, and Public Policy) and
initial Task Groups were formed. The several hundred
leaders and members of the NNDC—steadily grow-
ing—have been remarkably generous of time and
commitment. A difficult but critical first step was taken
in 2009–2010 with adoption of a standardized assess-
ment package, the common language or ‘‘vital signs’’ of
mental health, followed by establishment of a Data
Coordinating Center, formed with guidance and
participation of a Clinical Translational Science Award
(CTSA) team in one University. Growth in the
integrated data pool is now underway. Partnerships
with such federal agencies on local and national levels
arguably are a necessary prototype for the future.
The hundreds of faculty and staff from NNDC
member sites are currently collaborating in Task
Groups to address initial aims. Twelve are now
underway. Examples include Women and Mood,
evaluating depression during pregnancy, postpartum
TABLE 2. Criteria for individual centers of excellence
in the national network of depression centers
(February 2011)
1. A critical mass of interdisciplinary experts in depressive and bipolar
disorders
2. Formally establishing a Depression Center that integrates basic,
translational, clinical, and population-based research with clinical and
educational dissemination and outreach strategies;
3. Interdisciplinary participation from diverse schools and departments
within respective academic institutions, such as psychiatry, psychology,
family medicine, obstetrics, pediatrics, college student health, schools
of public health, nursing, pharmacy, social work, and others;
4. A large grant funding base focusing on depression, bipolar and related
conditions;
5. A dedication to translation of new findings to clinical delivery venues;
6. Substantial institutional commitment in the form of space, resources,
and authority provided to Center operations and the Director;
7. Community outreach, education, and training activities with special
efforts to reach underserved, rural, and neglected populations;
8. Commitment to support and participate in national network
collaborations with other Centers and other agencies (‘‘playing well
together in the sandbox’’)
TABLE 3. Members of the national network of
depression centers (February, 2011)





5. Johns Hopkins University
6. Massachusetts General Hospital, Partners HealthCare–Harvard
Medical School
7. Mayo Clinic
8. McLean Hospital, Partners HealthCare–Harvard Medical School
9. Medical University of South Carolina
10. Stanford University
11. University of California, San Francisco
12. University of Cincinnati & Lindner Center of HOPE
13. University of Colorado
14. Universwity of Illinois–Chicago
15. University of Iowa
16. University of Louisville
17. University of Massachusetts
18. University of Michigan
19. University of Pennsylvania
20. University of Texas Southwestern
21. Weill Cornell Medical College
618 Greden
Depression and Anxiety
period, and perinatal mood disturbances and using an
emergent registry for ongoing studies; Bipolar dis-
orders, with many of the sites collaborating with the
Prechter Bipolar Genetic Repository and with NIMH
support and other NNDC colleagues, emphasizing
longitudinal outcome biomarkers; Neuromodulation
for Treatment-Resistant Depressions (Electroconvul-
sive Therapy [ECT] and Transcranial Magnetic Sti-
mulation; Geriatric Mood Disorders; Mood disorders
screening and suicide prevention in schools; College
Mental Health; Intervention Dissemination and Health
Services; Military, Veterans and Families. Other Task
Groups to be launched in the near future include Child
and Adolescent Mood Disorders and Telehealth. An
NNDC scientific Journal is being discussed.
The Educational Domain Committee Task Groups
include: (1) ‘‘MoodBook,’’ a comprehensive, web-based
clearinghouse for Mood Disorders compiling and
organizing the preeminent information to improve
quality, trustworthiness, and availability for consumers
and clinicians; (2) Adolescent Depression Awareness
Program (ADAP), a School and Community Depres-
sion Prevention developed at Johns Hopkins and being
disseminated among a growing number sites; and (3)
College Mental Health Task Group.
To aid in transforming public policy, in late 2009, the
Public Policy Domain Committee completed a ‘‘white
paper’’ requested by a U.S. Senator about the lifesaving
and cost-saving potential of a network. Various NNDC
leaders provided requested consultation to those
writing subsequent legislation. The result was the
ENHANCED Act (Establishing a National Health-
Advancing Network of Centers of Excellence for
Depression), passed as part of the Patient Protection
and Affordability Act. Funding was projected to be
distributed via SAMHSA programs but has not yet
been finalized.
These initiatives were launched in the NNDC’s first
inaugural years; much more remains to be done.
MOTIVATIONS FOR NNDC
PARTICIPATION
What motivates NNDC participation? Member feed-
back indicates an altruistic conviction that a sustainable
network may be the only workable and affordable
solution to overcoming current small sample sizes,
research shortcomings, barriers in clinical translation,
and development of improved treatments[26,27] The
NNDC is perceived by many as already helping catalyze
stigma reduction in their home communities, enhancing
local research prowess and funding, recruiting a new
generation of stellar trainees, young investigators, and
faculty members, and becoming part of a strong,
evidence-based ‘‘voice.’’ The promise of entrepreneurial
opportunities and philanthropic support are additional
magnets. In communities with developing Depression
Centers, there is a palpable willingness to provide
financial support to help attack depression and bipolar
illnesses among a growing number of affected families
and while total reliance on this approach delays attain-
ment of the important aims, combining and leveraging
academic, federal, community, and philanthropic support
is a proven model for funding biomedical breakthroughs.
A VISION OF SUSTAINABLITY
Ongoing integration of research, clinical translation,
education, and public policy can only occur when coupled
with sustainability to attain and maintain public health
gains. Sustainability initially depends upon endorsement
by University leaders; an effective strategic plan; the
successful collection and integration of data that can be
used to address important questions; interdisciplinary
participation in research grants; scientific publications;
communication of positive accomplishments; and a solid
financial infrastructure. The latter will rely upon an array
of partnerships, including patients, families, university
schools and departments, foundations, corporations,
Figure 1. Map of the United States illustrating current locations of centers in the NNDC, National Network of Depression Centers.
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donors, advocacy groups, community groups, donors,
and federal agencies. The latter are demonstrated as vital
components for sustainability of other networks.
The NNDC’s aims are synergistic with those of
federal agencies and other entities invested in improving
our healthcare system. NNDC centers hold unique
capacity to leverage the aims of others and be a ‘‘force-
multiplier.’’ Following the policies of each agency, the
Network aims to compete for, propose, and respond to
research and service opportunities. National Institute of
Health (NIH) and Agency for Health Research Quality
(AHRQ) collaborations would help build and support
the integrated and sustainable research foundations that
are currently benefitting cancer, Alzheimer’s, Autism
Spectrum Disorders, and others. NIMH support of
sustainable networks may be especially essential.
SAMHSA funding, such as authorized in the EN-
HANCED Act, would enable dissemination to econom-
ically and geographically underserved populations and
aid such vital efforts as suicide prevention and services
for returning veterans and families, especially ‘‘citizen
soldiers’’ in the National Guard and Reserves (more than
40% of deployed troops), since most return to scattered
parts of the country and not to military bases where
medical care is readily available; partnerships with other
SAMHSA networks are also likely to produce incre-
mental gains and cost efficiencies;[28] CTSA partnerships
would accelerate translation and training. VAH and
DOD partnerships would further enable assessments
and service delivery for returning veteran populations.
These and other convictions at least partially explain
why participating NNDC Centers, lacking other sources
of financial support, have endorsed long-range perspec-
tives and despite financial struggles, agree to pay annual
dues to enable network development. Departments of
Psychiatry, traditionally cash-constrained, remain the
major sources of such dues, partially supported in some
Centers by other departments, Dean’s offices, or donors.
However, to achieve the progress needed, many more of
the above mentioned supporting partnerships are needed.
SUMMARY
America’s residents and those of the entire world
desperately need better strategies to attack depression
and bipolar illnesses. A national network of centers of
excellence with dissemination are models proven to have
profoundly beneficial medical and economic advantages
for other chronic diseases. Meaningful progress will only
occur through such partnerships because they alone will
address existing barriers. The NNDC was started to aid
in this effort to attack depressions, bipolar illnesses, and
related mood disorders (www.NNDC.org). To attain
sustainability and win the fight against depressions and
bipolar disorders, this new model requires support.
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